FDA Approval Roundup - December 2019
Last month the FDA approved ten new drugs aimed at treating a broad spectrum of diseases and ailments. The FDA often approves a number of drugs over a short period of time before the new year, with the group of approvals being aptly called "December Drugs". Check out the approvals below, and head to DrugBank.ca to learn more about them:
Dec 12, 2019 Golodirsen (DB15593)
FDA grants accelerated and conditional approval for Golodirsen, a drug for the treatment of Duchenne Muscular Dystrophy.
Dec 18, 2019 Enfortumab Vedotin (DB13007)
FDA grants accelerated approval to enfortumab vedotin, an antibody-drug conjugate for treatment-resistant urothelial cancers.
Dec 19, 2019 Levamlodipine (DB09237)
FDA approves levamlodipine, the pharmacologically active component of amlodipine.
Dec 19, 2019 Ebola Zaire Vaccine (DB15595)
FDA approves a live attenuated vaccine for the prevention of Zaire ebolavirus.
Dec 20, 2019 Lemborexant (DB11951)
FDA approves lemborexant, a dual orexin receptor antagonist for the treatment of insomnia.
Dec 20, 2019 Brilliant Blue G (DB15594)
FDA approves Brilliant Blue G for staining of the internal limiting membrane (ILM) of the eye.
Dec 20, 2019 Trastuzumab deruxtecan (DB14962)
FDA grants accelerated and conditional approval for Trastuzumab deruxtecan, a drug for the treatment of HER2 positive breast cancer.
Dec 20, 2019 Lumateperone (DB06077)
FDA approved Lumateperone, a second generation antipsychotic for the treatment of schizophrenia in adults.
Dec 23, 2019 Ubrogepant (DB15328)
FDA approves ubrogepant, the first oral CGRP antagonist approved for the acute treatment of migraines.
Jan 9, 2020 Avapritinib (DB15233)
FDA approves avapritinib, a selective tyrosine kinase inhibitor to treat unresectable, metastatic gastrointestinal stromal tumors.